Genentech/Roche's GA101 poised to usurp Rituxan in CLL
This article was originally published in Scrip
Genentech/Roche's novel product GA101 (obinutuzumab) is continuing its triumph over all challengers in its Phase III CLL11 study, producing significantly improved progression-free survival data over its predecessor MabThera/Rituxan (rituximab) in chronic lymphocytic leukaemia (CLL). However, the extent of its victory is still unclear – news on this will await presentation of the full results, probably at the American Society of Hematology meeting in December.
You may also be interested in...
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.